SlideShare a Scribd company logo
1 of 37
DRUG DESIGNING
BY: Raj K. Prasad (Gold Medalist)
SIP
Many physical, structural, and chemical
properties have been studied by the
QSAR approach, but the most common
are hydrophobic, electronic, and steric
properties. This is because it is possible to
quantify these effects.
The QSAR study then considers how
the hydrophobic, electronic, and
steric properties of the substituent’s
affect the biological activity are
called Descriptors.
Hydrophobicity is the association of non-polar groups
or molecules in an aqueous environment which arises
from the tendency of water to exclude non-polar
molecules.
The hydrophobic character of a drug is help to how
easily it crosses cell membranes and may also be
important in receptor interactions.
The relative hydrophilic/hydrophobic properties of a
drug are crucial in influencing its solubility,
absorption, distribution, metabolism, and excretion
(ADME).
S
I
P
Drugs which are too polar or too hydrophilic do
not cross the cell membranes of the gut wall
easily.
Changing substituents on a drug may well have
significant effects on its hydrophobic character
and which effect its biological activity.
So, it is important to the predicting this
quantitatively.
 Partition coefficients can be calculated by
knowing the contribution that various
substituent's make to Hydrophobicity.
 This contribution is known as the substituent
hydrophobicity constant (π) and is a measure of how
hydrophobic a substituent is relative to hydrogen.
 Partition coefficients are measured
experimentally for a standard compound, such as
benzene, with and without a substituent (X).
 The hydrophobicity constant (πX) for the
substituent (X) is then obtained using the
following equation:
where PH is the partition coefficient for the standard
compound and PX is the partition coefficient for the
standard compound with the substituent.
•A positive value of π indicates that the substituent
is more hydrophobic than hydrogen;
•A negative value indicates that the substituent is
less hydrophobic.
 The partition coefficient P is a measure of
the drug’s overall Hydrophobicity and is,
also measure of how efficiently a drug is
transported to its target and bound to its
binding site.
 The π value measures the
Hydrophobicity of a specific region on
the drug's skeleton.
 In the QSAR equation, indicate, important
hydrophobic interactions involving that
region of the molecule with the binding
site.
• Hydrophobic compounds have a high P value, whereas
hydrophilic compounds have a low P value.
•log P values are normally used as a measure of
hydrophobicity.
•Experimental procedures to determine log P include
HPLC
It is a measure of the
electron withdrawing
or electron-donating
ability of a substituent,
For examples-
dissociation of a string
of substituted benzoic
acids compared with
the dissociation of
benzoic acid itself.
 The Hammett substituent constant (σX) for a
particular substituent (X) is defined by the
following equation:
Substituents such as Cl, CN, or CF3 have
positive σ values
Substituents such as Me, Et, and t -Bu have
negative values of σ. The Hammett
substituent constant for H is zero.
 Example-
 Methyl ethanoate is the parent ester and it is
found that the rate of hydrolysis is affected by
the substituent X.
 -I groups reduce the rate of hydrolysis and,
have negative values (σI). For example, methyl,
ethyl, and propyl.
 Electron withdrawing groups increase the rate
of hydrolysis and have positive value. For CN,
F, Cl etc.
The bulk, size, and shape of a drug will
influence that, the drug how easily can
approach and interact with a binding site.
A bulky substituent may help to
orientation of a drug properly for
maximum binding and increase activity.
Steric properties are more difficult to
quantify than hydrophobic or electronic
properties.
 Taft’s steric factor (Es)
 Molar refractivity
 Verloop steric paramete
 The value for Es can be obtained by comparing the
rates of hydrolysis of substituted aliphatic esters
against a standard ester under acidic conditions.
Thus,
Where, kx represents the rate of
hydrolysis of an aliphatic ester
bearing the substituent X
and ko represents the rate of
hydrolysis of the reference ester
 Substituents which are larger than methyl
reduce the rate of hydrolysis (kx < ko), making
Es negative.
 A disadvantage of Es values is that they are a
measure of an intramolecular steric effect,
 whereas drugs interact with target binding sites
in an intermolecular manner.
 For example, think that Es values for isopropyl,
n-propyl, and n-Bu. The Es value for the
branched isopropyl group is significantly
greater than that for the linear n -propyl group.
 It measures the volume occupied by an atom or
a group of atoms.
 The MR is obtained from the following
equation:
where n is the index of refraction,
MW is the molecular weight, and d is the density.
The term MW/d defines a volume and the (n2−1)/(n2 + 2) term
provides a correction factor by defining how easily the substituent
can be polarized.
 Its measuring the steric factor using
STERIMOL (computer program ),
 which calculates steric substituent values
(Verloop steric parameters) from standard
bond angles, van der Waals radii, bond lengths,
and possible conformations for the substituent.
Ideally, the activities and properties are
connected by some known mathematical
function, F:
Biological activity =
F (physicochemical properties)
Biological activity can be any measure of,
such as C, Ki, IC50, ED50, and Km.
This equation shows that activity increases very slightly as the overall
hydrophobicity of the molecule (π sum) increases (the constant 0.14 is
low).
 The (π sum)2 term shows that there is an optimum overall
hydrophobicity for activity.
 The r2 value is 0.834 which is above the minimum acceptable value
of 0.8.
The estimation of physico‐chemical properties, biological
activities and understanding the physicochemical
features behind a biological response in drug design.
The rational design of numerous other products such as
surface‐active agents, perfumes, dyes, and fine chemicals.
The identification of hazardous compounds at early
stages of product development, the prediction of toxicity
to humans and environment.
The
general
form of
Hansch
equation
is as
follows:
Log BA = a log p + b σ + c Es + constant
(linear)
Log BA = a log p + b (log p)2 + c σ + d Es +
constant (nonlinear)
Hansch model correlates biological activity
with physicochemical properties.
The coefficients (a, b, c, d, and constant) are
determined by multiple regression analysis.
The constants k1 – k4 are determined by
computer software in order to get the best-
fitting equation.
 A model of the biological target may be built based
on the knowledge of what binds to it, and this
model in turn may be used to design new
molecular entities that interact with the target.
• The functional groups (critical portion of the
structure) of the drug that bind to the receptor
and produced biological activity are termed
“pharmacophores” or “pharmacophoric
groups.”
R1 an amino nitrogen is an essential feature of all opioids
because, in cationic conjugate acid form, it permits receptor
anchoring through an essential electrostatic bond with the
Asp residue conserved in all G protein–coupled receptors.
R2 phenolic hydroxyl group or a methoxy ether will be
found at C3 of all marketed multicyclic opioids because of
this phenol is required for binding at μ and kappa (k)
receptors.
Docking is the in silico
process by which a
molecular modelling
program fits a molecule
into a target binding site.
 Molecular modelling can be used to dock,
or fit, a molecule into a model of its
binding site.
 If the binding groups on the ligand and the
binding site are known, they can be defined
by the operator such that each binding
group in the ligand is paired with its
complementary group in the binding site.
 The DOCK program was one of the
earliest programs.
 The Connolly surface is first defined,
then the empty space of the binding site
is defined by identifying a collection of
differently sized spheres which will fill
up the space available and give a
‘negative image’ of the binding site
 Combinatorial chemistry is a technique by
which large numbers of different but
structurally similar molecules are produced
rapidly and submitted for pharmacological
assay.
 Combinatorial chemistry helps to produce
compound libraries to screen for novel
bioactivities.
These are as follows:
a. A cross-linked,
insoluble polymeric
material should be inert to
the condition of synthesis.
b. The linking substrate
(linker) to the solid phase
that permits selective
cleavage of some or all the
products from the solid
support during synthesis
for analysis of the extent
of reaction and ultimately
to give the final desirable
product.
c. The chemical
protection strategy must
allow selective protection
and de-protection of
reactive groups.
Solid-supported reagents are easily removed
from reactions by filtration.
Excess reagents can be used to drive reactions
to completion without introducing difficulties
in purification.
Recycling of recovered reagents is economical,
environmentally-sound, and efficient.
 The main problem of solution phase
combinatorial synthesis is to obtain pure
products.
 It was first used for easily synthesized
compound classes (amides, sulfonamides,
ureas, heterocycles).
No limitations of the
thermal or chemical
stability of the resin or
the linker.
Synthesis is shorter by
one or two steps.
Reactions in solution
often need considerably
less time.
Reactions can
conveniently be
followed by simple
means (TLC, NMR, UV).
Physicochemical properties (descriptors) in QSAR.pdf

More Related Content

What's hot

MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptx
MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptxMEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptx
MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptxRAJ K. MAURYA
 
c. Prostaglandins, Thromboxanes and Leukotrienes.pdf
c. Prostaglandins, Thromboxanes and Leukotrienes.pdfc. Prostaglandins, Thromboxanes and Leukotrienes.pdf
c. Prostaglandins, Thromboxanes and Leukotrienes.pdfVISHALJADHAV100
 
Monoclonal antibodies as drug targeting particulate carrier system
Monoclonal antibodies as drug targeting particulate carrier systemMonoclonal antibodies as drug targeting particulate carrier system
Monoclonal antibodies as drug targeting particulate carrier systemKrutika Pardeshi
 
COMPUTER AIDED DRUG DEVELOPMENT
COMPUTER  AIDED DRUG DEVELOPMENTCOMPUTER  AIDED DRUG DEVELOPMENT
COMPUTER AIDED DRUG DEVELOPMENTJyotiMhoprekar
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)Shikha Popali
 
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...ThePharmaFacts
 
Compartment modeling ppt
Compartment modeling pptCompartment modeling ppt
Compartment modeling pptbinu anand
 
DRUG METABOLISM-MEDICINAL CHEMISTRY
DRUG METABOLISM-MEDICINAL CHEMISTRYDRUG METABOLISM-MEDICINAL CHEMISTRY
DRUG METABOLISM-MEDICINAL CHEMISTRYNavdha Soni
 
Nasal drug delivery
Nasal drug deliveryNasal drug delivery
Nasal drug deliveryGaurav Kr
 
Quality assurance unit 5.pdf
Quality assurance unit 5.pdfQuality assurance unit 5.pdf
Quality assurance unit 5.pdfEssamZatout1
 
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]Shikha Popali
 
Concept of Prodrugs.pptx
Concept of Prodrugs.pptxConcept of Prodrugs.pptx
Concept of Prodrugs.pptxAbhijeet Daf
 

What's hot (20)

Hepatic metabolism rate
Hepatic metabolism rateHepatic metabolism rate
Hepatic metabolism rate
 
MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptx
MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptxMEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptx
MEDICINAL CHEMISTRY OF ANTI-TUBERCULAR AGENTS.pptx
 
c. Prostaglandins, Thromboxanes and Leukotrienes.pdf
c. Prostaglandins, Thromboxanes and Leukotrienes.pdfc. Prostaglandins, Thromboxanes and Leukotrienes.pdf
c. Prostaglandins, Thromboxanes and Leukotrienes.pdf
 
Monoclonal antibodies as drug targeting particulate carrier system
Monoclonal antibodies as drug targeting particulate carrier systemMonoclonal antibodies as drug targeting particulate carrier system
Monoclonal antibodies as drug targeting particulate carrier system
 
COMPUTER AIDED DRUG DEVELOPMENT
COMPUTER  AIDED DRUG DEVELOPMENTCOMPUTER  AIDED DRUG DEVELOPMENT
COMPUTER AIDED DRUG DEVELOPMENT
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)
 
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...
Basic Concepts & Application of Prodrugs Design [Antiviral,Antibiotics,GPAT Q...
 
Qsar studies
Qsar studiesQsar studies
Qsar studies
 
Gene therapy
Gene therapy   Gene therapy
Gene therapy
 
Compartment modeling ppt
Compartment modeling pptCompartment modeling ppt
Compartment modeling ppt
 
DRUG METABOLISM-MEDICINAL CHEMISTRY
DRUG METABOLISM-MEDICINAL CHEMISTRYDRUG METABOLISM-MEDICINAL CHEMISTRY
DRUG METABOLISM-MEDICINAL CHEMISTRY
 
Nasal drug delivery
Nasal drug deliveryNasal drug delivery
Nasal drug delivery
 
Quality assurance unit 5.pdf
Quality assurance unit 5.pdfQuality assurance unit 5.pdf
Quality assurance unit 5.pdf
 
Macroloid antibiotics
Macroloid antibioticsMacroloid antibiotics
Macroloid antibiotics
 
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]
OLIGONUCLEOTIDE THERAPY [ TECHNIQUES, APPLICATIONS]
 
Prodrug
ProdrugProdrug
Prodrug
 
Prodrug
ProdrugProdrug
Prodrug
 
Antiulcer
AntiulcerAntiulcer
Antiulcer
 
PRODRUG DESIGN.pptx
PRODRUG  DESIGN.pptxPRODRUG  DESIGN.pptx
PRODRUG DESIGN.pptx
 
Concept of Prodrugs.pptx
Concept of Prodrugs.pptxConcept of Prodrugs.pptx
Concept of Prodrugs.pptx
 

Similar to Physicochemical properties (descriptors) in QSAR.pdf

Similar to Physicochemical properties (descriptors) in QSAR.pdf (20)

Ligand based drug design
Ligand based drug designLigand based drug design
Ligand based drug design
 
Qsar UMA
Qsar   UMAQsar   UMA
Qsar UMA
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
Insilico methods for design of novel inhibitors of Human leukocyte elastase
Insilico methods for design of novel inhibitors of Human leukocyte elastaseInsilico methods for design of novel inhibitors of Human leukocyte elastase
Insilico methods for design of novel inhibitors of Human leukocyte elastase
 
Quantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptxQuantitative Structure Activity Relationship.pptx
Quantitative Structure Activity Relationship.pptx
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
QSAR Studies presentation
 QSAR Studies presentation QSAR Studies presentation
QSAR Studies presentation
 
Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)Quantative Structure-Activity Relationships (QSAR)
Quantative Structure-Activity Relationships (QSAR)
 
QSAR : Activity Relationships Quantitative Structure
QSAR : Activity Relationships Quantitative StructureQSAR : Activity Relationships Quantitative Structure
QSAR : Activity Relationships Quantitative Structure
 
Qsar
QsarQsar
Qsar
 
Lecture 6
Lecture 6Lecture 6
Lecture 6
 
QSAR by hansch analysis
QSAR by hansch analysisQSAR by hansch analysis
QSAR by hansch analysis
 
Qsar
QsarQsar
Qsar
 
Qsar ppt
Qsar pptQsar ppt
Qsar ppt
 
QSAR.pptx
QSAR.pptxQSAR.pptx
QSAR.pptx
 
QSAR
QSARQSAR
QSAR
 
QSAR
QSARQSAR
QSAR
 
Introduction to Drug Design
 Introduction to Drug Design Introduction to Drug Design
Introduction to Drug Design
 
Lecture 5
Lecture 5Lecture 5
Lecture 5
 
Qsar parameter
Qsar parameterQsar parameter
Qsar parameter
 

More from RAJ K. MAURYA

corticosteroids.pptx
corticosteroids.pptxcorticosteroids.pptx
corticosteroids.pptxRAJ K. MAURYA
 
Chemistry of sex hormones.pptx
Chemistry of sex hormones.pptxChemistry of sex hormones.pptx
Chemistry of sex hormones.pptxRAJ K. MAURYA
 
chemistry of diuretics.pptx
chemistry of diuretics.pptxchemistry of diuretics.pptx
chemistry of diuretics.pptxRAJ K. MAURYA
 
The-Future-of-AI-in-Drug-Discovery.pptx
The-Future-of-AI-in-Drug-Discovery.pptxThe-Future-of-AI-in-Drug-Discovery.pptx
The-Future-of-AI-in-Drug-Discovery.pptxRAJ K. MAURYA
 
Chemistry of anti protozoal drugs.pdf
Chemistry of anti protozoal drugs.pdfChemistry of anti protozoal drugs.pdf
Chemistry of anti protozoal drugs.pdfRAJ K. MAURYA
 
chemistry of anti fungal.pptx
chemistry of anti fungal.pptxchemistry of anti fungal.pptx
chemistry of anti fungal.pptxRAJ K. MAURYA
 
Chemistry of Sulphonamide.pptx
Chemistry of Sulphonamide.pptxChemistry of Sulphonamide.pptx
Chemistry of Sulphonamide.pptxRAJ K. MAURYA
 
Medicinal chemistry of Macrolide.pptx
Medicinal chemistry of Macrolide.pptxMedicinal chemistry of Macrolide.pptx
Medicinal chemistry of Macrolide.pptxRAJ K. MAURYA
 
MEDICINAL CHEMISTRY OF QUINOLONES.pptx
MEDICINAL CHEMISTRY OF QUINOLONES.pptxMEDICINAL CHEMISTRY OF QUINOLONES.pptx
MEDICINAL CHEMISTRY OF QUINOLONES.pptxRAJ K. MAURYA
 
chemistry and synthesis of methotrexate.pptx
chemistry and synthesis of methotrexate.pptxchemistry and synthesis of methotrexate.pptx
chemistry and synthesis of methotrexate.pptxRAJ K. MAURYA
 

More from RAJ K. MAURYA (11)

corticosteroids.pptx
corticosteroids.pptxcorticosteroids.pptx
corticosteroids.pptx
 
Chemistry of sex hormones.pptx
Chemistry of sex hormones.pptxChemistry of sex hormones.pptx
Chemistry of sex hormones.pptx
 
chemistry of diuretics.pptx
chemistry of diuretics.pptxchemistry of diuretics.pptx
chemistry of diuretics.pptx
 
The-Future-of-AI-in-Drug-Discovery.pptx
The-Future-of-AI-in-Drug-Discovery.pptxThe-Future-of-AI-in-Drug-Discovery.pptx
The-Future-of-AI-in-Drug-Discovery.pptx
 
Chemistry of anti protozoal drugs.pdf
Chemistry of anti protozoal drugs.pdfChemistry of anti protozoal drugs.pdf
Chemistry of anti protozoal drugs.pdf
 
chemistry of anti fungal.pptx
chemistry of anti fungal.pptxchemistry of anti fungal.pptx
chemistry of anti fungal.pptx
 
Chemistry of Sulphonamide.pptx
Chemistry of Sulphonamide.pptxChemistry of Sulphonamide.pptx
Chemistry of Sulphonamide.pptx
 
Medicinal chemistry of Macrolide.pptx
Medicinal chemistry of Macrolide.pptxMedicinal chemistry of Macrolide.pptx
Medicinal chemistry of Macrolide.pptx
 
MEDICINAL CHEMISTRY OF QUINOLONES.pptx
MEDICINAL CHEMISTRY OF QUINOLONES.pptxMEDICINAL CHEMISTRY OF QUINOLONES.pptx
MEDICINAL CHEMISTRY OF QUINOLONES.pptx
 
Anti viral drug.pdf
Anti viral drug.pdfAnti viral drug.pdf
Anti viral drug.pdf
 
chemistry and synthesis of methotrexate.pptx
chemistry and synthesis of methotrexate.pptxchemistry and synthesis of methotrexate.pptx
chemistry and synthesis of methotrexate.pptx
 

Recently uploaded

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1DR SETH JOTHAM
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communicationskatiequigley33
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Anjali Parmar
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxSamar Tharwat
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSuresh Kumar K
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthCatherine Liao
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...marcuskenyatta275
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumassuser144901
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answersShafnaP5
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenRaju678948
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingMedicoseAcademics
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale nowSherrylee83
 
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...marcuskenyatta275
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYDRPREETHIJAMESP
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptxSabbu Khatoon
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPupayumnam1
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...marcuskenyatta275
 

Recently uploaded (20)

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 

Physicochemical properties (descriptors) in QSAR.pdf

  • 1. DRUG DESIGNING BY: Raj K. Prasad (Gold Medalist) SIP
  • 2. Many physical, structural, and chemical properties have been studied by the QSAR approach, but the most common are hydrophobic, electronic, and steric properties. This is because it is possible to quantify these effects. The QSAR study then considers how the hydrophobic, electronic, and steric properties of the substituent’s affect the biological activity are called Descriptors.
  • 3. Hydrophobicity is the association of non-polar groups or molecules in an aqueous environment which arises from the tendency of water to exclude non-polar molecules. The hydrophobic character of a drug is help to how easily it crosses cell membranes and may also be important in receptor interactions. The relative hydrophilic/hydrophobic properties of a drug are crucial in influencing its solubility, absorption, distribution, metabolism, and excretion (ADME). S I P
  • 4. Drugs which are too polar or too hydrophilic do not cross the cell membranes of the gut wall easily. Changing substituents on a drug may well have significant effects on its hydrophobic character and which effect its biological activity. So, it is important to the predicting this quantitatively.
  • 5.  Partition coefficients can be calculated by knowing the contribution that various substituent's make to Hydrophobicity.  This contribution is known as the substituent hydrophobicity constant (π) and is a measure of how hydrophobic a substituent is relative to hydrogen.  Partition coefficients are measured experimentally for a standard compound, such as benzene, with and without a substituent (X).
  • 6.  The hydrophobicity constant (πX) for the substituent (X) is then obtained using the following equation: where PH is the partition coefficient for the standard compound and PX is the partition coefficient for the standard compound with the substituent. •A positive value of π indicates that the substituent is more hydrophobic than hydrogen; •A negative value indicates that the substituent is less hydrophobic.
  • 7.
  • 8.  The partition coefficient P is a measure of the drug’s overall Hydrophobicity and is, also measure of how efficiently a drug is transported to its target and bound to its binding site.  The π value measures the Hydrophobicity of a specific region on the drug's skeleton.  In the QSAR equation, indicate, important hydrophobic interactions involving that region of the molecule with the binding site.
  • 9. • Hydrophobic compounds have a high P value, whereas hydrophilic compounds have a low P value. •log P values are normally used as a measure of hydrophobicity. •Experimental procedures to determine log P include HPLC
  • 10. It is a measure of the electron withdrawing or electron-donating ability of a substituent, For examples- dissociation of a string of substituted benzoic acids compared with the dissociation of benzoic acid itself.
  • 11.  The Hammett substituent constant (σX) for a particular substituent (X) is defined by the following equation: Substituents such as Cl, CN, or CF3 have positive σ values Substituents such as Me, Et, and t -Bu have negative values of σ. The Hammett substituent constant for H is zero.
  • 12.  Example-  Methyl ethanoate is the parent ester and it is found that the rate of hydrolysis is affected by the substituent X.  -I groups reduce the rate of hydrolysis and, have negative values (σI). For example, methyl, ethyl, and propyl.
  • 13.  Electron withdrawing groups increase the rate of hydrolysis and have positive value. For CN, F, Cl etc.
  • 14. The bulk, size, and shape of a drug will influence that, the drug how easily can approach and interact with a binding site. A bulky substituent may help to orientation of a drug properly for maximum binding and increase activity. Steric properties are more difficult to quantify than hydrophobic or electronic properties.
  • 15.  Taft’s steric factor (Es)  Molar refractivity  Verloop steric paramete
  • 16.  The value for Es can be obtained by comparing the rates of hydrolysis of substituted aliphatic esters against a standard ester under acidic conditions. Thus, Where, kx represents the rate of hydrolysis of an aliphatic ester bearing the substituent X and ko represents the rate of hydrolysis of the reference ester
  • 17.  Substituents which are larger than methyl reduce the rate of hydrolysis (kx < ko), making Es negative.  A disadvantage of Es values is that they are a measure of an intramolecular steric effect,  whereas drugs interact with target binding sites in an intermolecular manner.  For example, think that Es values for isopropyl, n-propyl, and n-Bu. The Es value for the branched isopropyl group is significantly greater than that for the linear n -propyl group.
  • 18.  It measures the volume occupied by an atom or a group of atoms.  The MR is obtained from the following equation: where n is the index of refraction, MW is the molecular weight, and d is the density. The term MW/d defines a volume and the (n2−1)/(n2 + 2) term provides a correction factor by defining how easily the substituent can be polarized.
  • 19.  Its measuring the steric factor using STERIMOL (computer program ),  which calculates steric substituent values (Verloop steric parameters) from standard bond angles, van der Waals radii, bond lengths, and possible conformations for the substituent.
  • 20. Ideally, the activities and properties are connected by some known mathematical function, F: Biological activity = F (physicochemical properties) Biological activity can be any measure of, such as C, Ki, IC50, ED50, and Km.
  • 21. This equation shows that activity increases very slightly as the overall hydrophobicity of the molecule (π sum) increases (the constant 0.14 is low).  The (π sum)2 term shows that there is an optimum overall hydrophobicity for activity.  The r2 value is 0.834 which is above the minimum acceptable value of 0.8.
  • 22. The estimation of physico‐chemical properties, biological activities and understanding the physicochemical features behind a biological response in drug design. The rational design of numerous other products such as surface‐active agents, perfumes, dyes, and fine chemicals. The identification of hazardous compounds at early stages of product development, the prediction of toxicity to humans and environment.
  • 23. The general form of Hansch equation is as follows: Log BA = a log p + b σ + c Es + constant (linear) Log BA = a log p + b (log p)2 + c σ + d Es + constant (nonlinear) Hansch model correlates biological activity with physicochemical properties. The coefficients (a, b, c, d, and constant) are determined by multiple regression analysis.
  • 24. The constants k1 – k4 are determined by computer software in order to get the best- fitting equation.
  • 25.  A model of the biological target may be built based on the knowledge of what binds to it, and this model in turn may be used to design new molecular entities that interact with the target. • The functional groups (critical portion of the structure) of the drug that bind to the receptor and produced biological activity are termed “pharmacophores” or “pharmacophoric groups.”
  • 26. R1 an amino nitrogen is an essential feature of all opioids because, in cationic conjugate acid form, it permits receptor anchoring through an essential electrostatic bond with the Asp residue conserved in all G protein–coupled receptors. R2 phenolic hydroxyl group or a methoxy ether will be found at C3 of all marketed multicyclic opioids because of this phenol is required for binding at μ and kappa (k) receptors.
  • 27. Docking is the in silico process by which a molecular modelling program fits a molecule into a target binding site.
  • 28.  Molecular modelling can be used to dock, or fit, a molecule into a model of its binding site.  If the binding groups on the ligand and the binding site are known, they can be defined by the operator such that each binding group in the ligand is paired with its complementary group in the binding site.
  • 29.  The DOCK program was one of the earliest programs.  The Connolly surface is first defined, then the empty space of the binding site is defined by identifying a collection of differently sized spheres which will fill up the space available and give a ‘negative image’ of the binding site
  • 30.
  • 31.  Combinatorial chemistry is a technique by which large numbers of different but structurally similar molecules are produced rapidly and submitted for pharmacological assay.  Combinatorial chemistry helps to produce compound libraries to screen for novel bioactivities.
  • 32.
  • 33. These are as follows: a. A cross-linked, insoluble polymeric material should be inert to the condition of synthesis. b. The linking substrate (linker) to the solid phase that permits selective cleavage of some or all the products from the solid support during synthesis for analysis of the extent of reaction and ultimately to give the final desirable product. c. The chemical protection strategy must allow selective protection and de-protection of reactive groups.
  • 34. Solid-supported reagents are easily removed from reactions by filtration. Excess reagents can be used to drive reactions to completion without introducing difficulties in purification. Recycling of recovered reagents is economical, environmentally-sound, and efficient.
  • 35.  The main problem of solution phase combinatorial synthesis is to obtain pure products.  It was first used for easily synthesized compound classes (amides, sulfonamides, ureas, heterocycles).
  • 36. No limitations of the thermal or chemical stability of the resin or the linker. Synthesis is shorter by one or two steps. Reactions in solution often need considerably less time. Reactions can conveniently be followed by simple means (TLC, NMR, UV).